Quotient Biodiagnostics Receives FDA License to Sell a Range of Rare Polyclonal Antisera Products in the U.S.A.

Published: Oct 05, 2012

NEWTOWN, Pa.--(BUSINESS WIRE)--Quotient Biodiagnostics, Inc. (“Quotient”), a supplier of innovative and high-quality transfusion diagnostic products to hospitals, blood banks and other healthcare institutions, is pleased to announce that its range of ALBAsera® Rare Antisera products have been licensed for sale by the U.S. Food and Drug Administration (FDA). “The licensing of the ALBAsera® rare antisera products by the FDA is yet another important milestone achieved by Quotient this year”, said Jeremy Stackawitz, President and CEO of Quotient. “The launch of these products allows us to better meet our customers’ needs and advances our progress towards being the premier provider of manual transfusion diagnostics products in the U.S.”

Back to news